New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
08:40 EDTBMRNBioMarin doses first patient in Phase 3 INSPIRE trial with BMN 701
BioMarin announced that it has dosed the first patient with BMN 701 in the Phase 3 INSPIRE trial for Pompe disease. BMN 701 is a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidas, designed to target delivery to the lysosomes where the enzyme is most needed. The INSPIRE trial focuses on late onset Pompe disease an inherited condition caused by a deficiency in the lysosomal enzyme acid alpha glucosidase, which can lead to progressive weakening of the muscles of the body, including the diaphragm, a crucial respiratory muscle. Respiratory impairment is the leading cause of morbidity and mortality in late onset Pompe disease.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:55 EDTBMRNBioMarin shares poised to rally, says RBC Capital
RBC Capital expects BioMarin's shares to rally into and through 2015, driven by 4-5 key pipeline events. The firm is especially upbeat on the outlook for Phase II achondroplasia data in 2Q15, as it thinks the product could show promising efficacy in dwarfism. The firm raised its price target on the name to $87 from $77 and keeps an Outperform rating on the shares.
07:44 EDTBMRNBioMarin price target raised to $87 from $74 at UBS
UBS raised its price target on BioMarin to $87 from $74 following its Q3 report and the firm believes the price target could be conservative based on the company's pipeline and its lower risk businesses. UBS reiterates its Buy rating on BioMarin shares.
05:50 EDTBMRNBioMarin remains a top mid cap pick at Piper Jaffray
Subscribe for More Information
October 23, 2014
16:17 EDTBMRNBioMarin lowers FY14 adjusted net loss to ($65M)-($50M) from ($80M)-($60M)
Subscribe for More Information
16:15 EDTBMRNBioMarin raises FY14 revenue view to $700M-$710M from $680M-$700M
Subscribe for More Information
16:13 EDTBMRNBioMarin reports Q3 adjusted EPS (16c), consensus (23c)
Subscribe for More Information
15:30 EDTBMRNNotable companies reporting after market close
Subscribe for More Information
October 21, 2014
09:48 EDTBMRNShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
October 20, 2014
07:10 EDTBMRNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use